Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (28)

B-05Lorenzo Contento

Improving simulations by learning the true random effects’ distribution from a population using generative machine learning

Wednesday 9:00-9:20

B-06Sam Richardson

Automating Population Pharmacokinetic Model Development using Machine Learning

Wednesday 9:20-9:40

B-07Gilbert Koch

Learning from machine learning – how to deduce a mechanism-based pharmacometrics model for serum creatinine in preterm neonates from neural ordinary differential equations

Wednesday 9:40-10:00

B-08Ercan Suekuer

PMx-AI Bot: Changing the way of traditional Pharmacometrics work with AI Bots

Wednesday 10:00-10:20

B-11Paolo Denti

Handling within-subject/between-occasion variability in longitudinal data: Common Challenges and Practical Solutions

Wednesday 11:50-12:30

B-14Samer Mouksassi

Streamlining Clinical Development of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Pediatric Chronic Kidney Disease Patients by Integration of Clinical Trial and Real-World Data

Wednesday 14:20-14:40

B-14Pascal Chanu

A disease model for Multiple Myeloma developed using Real World Data and validated on Phase 3 clinical trials

Wednesday 14:00-14:20

B-15Luca Marzano

Overcoming the discrepancies between clinical trials and real-world data of small cell lung cancer chemotherapy. A data-driven approach to learn across real-world evidence studies

Wednesday 14:40-15:00

B-16Aole Zheng

A Novel Approach Using Pharmacometrics/Pharmacoeconomic (PMPE) Model for Cost-effectiveness Analysis of Tacrolimus-Diltiazem Combination in Liver Transplant Patients: Evidence from Real-world Clinical Data

Wednesday 15:00-15:20

B-18Alzahra Hamdan

Integrated modeling of digital-motor outcomes and clinical outcome assessments using IRT: a framework for developing better outcomes for clinical trials in rare neurological diseases

Wednesday 16:50-17:10

B-20Marina Savelieva

Virtual Patient Cohorts using Modeling and Simulation to support drug development in rare diseases

Wednesday 17:10-17:30

C-02Wendy Chu

Optimizing dosing strategies for post-kala-azar dermal leishmaniasis: a geographical comparison of systemic and skin pharmacokinetics and pharmacodynamics of antileishmanial drugs

Thursday 8:30-8:55

C-03Selma El Messaoudi

Mechanistic modeling of the long-term dynamics of viral markers to predict the outcome of combination therapy in chronic HBV and HDV infections

Thursday 8:55-9:20

C-04Julie Dudasova

Logistic regression-based approach to assess heterogeneity in vaccine efficacy using immunogenicity measurements in phase 3 clinical trials

Thursday 9:20-9:45

C-08Rik Schoemaker

Quantification of the analgesic effect of intranasal coadministration of ketamine and sufentanil in adults to support the development of a pain relief treatment (CT001) in children

Thursday 11:20-11:40

C-09Sandrine Boulet

Bayesian framework for multi-source data integration – application to Human extrapolation from preclinical studies

Thursday 11:40-12:00

C-10Laila Nassar

Pharmacokinetics During Hemodialysis and Hemodiafiltration: Dialysis Clearance is more important than Dialysis Efficiency – Application to Amikacin

Thursday 12:00-12:20

C-11Davide Bindellini

From physiology to disease: A quantitative framework for system-disease-drug interaction in cortisol replacement therapy

Thursday 12:20-12:40

C-14Javier Sanchez Fernandez

Optimizing Molecule Design for Bispecific Antibodies in Immuno-Oncology: A Case Study with FAP-4-1BBL

Thursday 14:10-14:30

C-15Robin Haid

Transforming the discovery of targeted protein degraders: the translational power of predictive PK/PD modeling

Thursday 14:30-14:50

C-19Auriane Gabaut

High-dimension Mechanistic Model Building using LASSO Approaches : Application to Ebola Vaccination

Thursday 16:30-16:50

C-20Nelleke Snelder

Time-varying covariates, mediation analysis and overadjustment bias in PK/PD modelling

Thursday 16:50-17:10

C-21Mohamed Tarek

Make models great again by optimally restricting parameters to make non-identifiable models provably identifiable

Thursday 17:10-17:30

D-02Lorenzo Dasti

A Quantitative System Pharmacology model for the development and optimization of mRNA vaccines.

Friday 9:15-9:35

D-03Erwin Dreesen

A patient stratification tool for selecting tuberculosis treatment regimen composition and duration

Friday 9:35-9:55

D-04Carlos Olivares

Mathematical Modeling Of Gut Microbiota Diversity Under The Effects of Beta-lactam Antibiotics

Friday 9:55-10:15

D-08Ruben Taieb

Mechanistic modelling of tumor kinetics coupled with biomarker dynamics for survival prediction in non-small cell lung cancer patients

Friday 11:05-11:25

D-09Elisabeth Rouits

Incorporating clinical utility and Pharmacokinetics (PK)/Pharmacodynamics (PD) in clinical development of oncology drug candidate with a Bayesian decision analysis perspective in the context of OPTIMUS initiative

Friday 11:25-11:45